CoreLab Partners Announces Its Entry Into the Early Alzheimer's Imaging Market Space
CoreLab Partners, Inc, an independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer’s disease.
“Recognizing the ongoing evolution of magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging in dementia-related clinical trials, CoreLab Partners has put into place a team of knowledgeable experts combined with advanced technological tools to ensure current and emerging image assessment needs are met” stated Dr. Michael Woehler, President & CEO. “This exciting new capability is a natural extension of our industry-leading suite of imaging science solutions and marks a significant milestone in the utilization of scientifically validated tools designed to accurately quantify brain structure volumetric data” added Woehler.
Senior members of the CoreLab Partners’ medical affairs team will be attending CBIs upcoming 6th Annual Alzheimer’s Drug Development Summit to be held in Philadelphia, PA from December 11 – 12, 2012; please join us for this important industry event as the scientific community shares their future perspectives from the Dominantly Inherited Alzheimer Network (DIAN).
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
